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Background: Predictive factors of rituximab efficacy and its effect on the immune system are still
not defined.
Patients and methods: Three hundred and six patients with follicular or mantle cell lymphoma
received four weekly doses of rituximab (induction) and no further treatment (arm A) or four more
doses at 2-month intervals (arm B).
Results: Response rate to induction was 44%. Independent predictive factors for response were disease
bulk <5 cm, follicular histology, normal hemoglobin and low lymphocyte count. Factors associated
with event-free survival (EFS) were having responded to induction, having received not more than one
line of therapy, Ann Arbor stage I–III, high lymphocyte count, disease bulk <5 cm, Fc-gamma receptor
genotype VV and receiving prolonged treatment. B cells were suppressed by treatment but recovered
after a median of 12 months in arm A and 18 months in arm B. The median IgM level after 1 year was
normal in arm A but was decreased to 73% of baseline in arm B. We observed 24 serious adverse
events, equally distributed between arms. Ten patients receiving induction only and six patients
receiving prolonged treatment developed a second tumor.
Conclusions: We defined the characteristics predicting response and EFS to rituximab. Prolonged
treatment results in longer EFS at the cost of a longer reduction in B cell and IgM levels, but without
additional clinical toxicity.
Key words: rituximab, predictive factors, toxicity, Fc-c receptor, follicular lymphoma, mantle cell
lymphoma
Introduction
Follicular (FL) and mantle cell lymphomas (MCL) are usually
considered incurable diseases. Even though aggressive inter-
ventions such as autologous or allogeneic transplantation may
prolong survival or eventually cure some patients [1, 2], in
the majority of cases treatment is aimed at relieving or pre-
venting symptoms [3, 4]. Many treatment options are now avail-
able, ranging from relatively simple and well tolerated single
agent regimens to complex and possibly toxic combination
chemo(immuno)therapies. In this mainly palliative setting,
many physicians believe that the optimal treatment is one pro-
ducing the least side-effects while obtaining a long time without
symptoms of disease.
Single agent rituximab is one of these options, having been
shown to cause little toxicity and to obtain, given at a prolonged
schedule and in some patient subsets, remissions that are com-
parable to what is obtained with multi-agent regimens [5, 6].
However, many are still reluctant in applying single-agent im-
munotherapy, fearing an insufficient activity compared with
other more traditional schemes.
The efficacy of antibody treatment was shown to differ among
lymphoma subtypes, but the reason why some histologies re-
spond better than others has not been clarified. Due to the dif-
ferent mechanisms of action of monoclonal antibodies, it is
possible that some mechanisms are more effective against some
tumor types than against others, but it could as well be that
certain histologies are more associated with biological or
clinical characteristics of the patient that influence treatment
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response. Furthermore, a prospective and prolonged observation
of relevant clinical and immunological side-effects in a large
cohort of patients treated with the single agent has not been
reported.
We therefore analyzed an important number of characteristics
of 306 patients with FL or MCL and of their disease that could
predict benefit from treatment with single-agent rituximab,
based on data of the SAKK trial 35/98. We also describe the
observed short and long-term major side-effects. This explor-
atory analysis intended to identify potential factors that are
associated with response, event-free survival (EFS) and toxicity.
Patients and methods
Trial design
This trial consisted of two subtrials: one for FL and one for MCL patients.
The trial treatment and assessment schedule were identical in both subtrials.
Patients were enrolled from January 1998 to January 2002 in 29 institutions.
The trial was approved by the local ethics committee of each participating
institution and conducted in accordance with the Declaration of Helsinki
and currently applicable amendments. All patients gave written informed
consent.
Patients were initially treated with rituximab 375 mg/m2 per week for
4 weeks (‘induction’ phase). Patients with stable disease or in partial or
complete response at week 12 (from treatment start) were randomized in
a 1:1 ratio into two groups: no further treatment (arm A, ‘standard treat-
ment’) or treatment with a single infusion of rituximab 375 mg/m2 at week
12, and again at months 5, 7 and 9 (arm B, ‘prolonged treatment’). The
randomization was stratified according to status of disease at trial entry (first
presentation versus refractory or relapsed), response to induction treat-
ment (stable disease versus response) and center. Patients were centrally
randomized by the minimization method via fax at the SAKK Coordinating
Center in Bern. Upon disease progression or relapse, further treatment was
at the treating physician’s discretion.
EFS time was the primary end point and calculated as the time from first
induction infusion to progression, relapse, second tumor or death from any
cause. For the randomized phase of the two subtrials, a group sequential
design with two interim analyses and one final analysis was adopted. Both
subtrials reached the final stage.
Patients
Inclusion criteria were a biopsy-proven follicular or mantle cell lymphoma,
age ‡18 years and measurable disease defined as the presence of at least
one previously unirradiated lesion with two measurable perpendicular diam-
eters of which at least one should be of 2 cm. The interval between the last
systemic anticancer treatment and trial entry should not be less than 28 days.
Other inclusion criteria were an Eastern Cooperative Oncology Group
(ECOG) performance status £2 and, after observing unexpected cardiac
events in the first 10 months of the trial [7], a cardiac ejection fraction
(EF) ‡50% by echocardiography. Exclusion criteria included symptomatic
central nervous system (CNS) disease, a history of significant medical con-
ditions, including previous malignancies within 5 years, a reduced renal
function (creatinine >2· the upper limit of normal [ULN]) or liver function
(bilirubin >2· ULN). Pregnant or lactating females, patients with active
opportunistic infections or patients with known HIV, hepatitis B or C infec-
tions were also excluded. Previous treatment with rituximab was not
allowed. A central histology review was performed for all cases before
randomization.
Trial assessments
The detailed examinations required by the trials are described elsewhere
[5, 6]. Briefly, patients underwent a complete staging at trial entry, which
was repeated at 12 weeks, and at 7, 12, 18 and 24 months, then yearly or
when clinically required. Re-evaluation of the bone marrow (BM) was re-
quired only at week 12 and month 12 if involved at trial entry. Routine blood
counts and chemistries were assessed at baseline, before each rituximab
administration and at months 2, 3, 5, 7, 9 and 12. Serum immunoglobulins
(IgG, IgA, IgM) were measured at baseline and again at months 3, 7 and 12,
while blood samples for immunophenotyping were taken at baseline, week
12 and months 9, 12, 18 and 24. Analysis of lymphocyte subsets was per-
formed as described before [5].
Statistical methods
To identify factors predictive of response to rituximab induction and EFS,
we first performed preliminary univariate analyses (logistic regression for
response and Cox regression for EFS) on the factors listed in Table 1. For
EFS (only randomized patients were considered), further models including
an additional covariate for treatment arm, with or without treatment-factor
interaction, were also explored as suggested in [8]. We then selected among
the factors and interactions via a stepwise procedure with entry criterion
P value = 0.1 and stay criterion P value = 0.05. Finally we refit the models
using data from all patients seen with non-missing values for the selected
variables. Due to correlations between some variables (e.g. disease bulk at
baseline and disease bulk at randomization) and numerous missing values,
some factors were excluded prior to the selection procedure in order to
increase model stability. The pre and post differences of lymphocyte subset
counts were analyzed by the Wilcoxon signed rank test. The between-arm
differences of immunoglobulin levels were compared by the Wilcoxon rank
sum test. No adjustment for multiple testing was performed, therefore the
reported P values should be interpreted with caution.
Prediction score
To construct a prediction score that could help clinicians select the right
candidates for single-agent rituximab, we randomly selected 206 (‘training
set’) out of the pooled cohort of 306 patients and repeated the above model-
building procedure to select predictive baseline clinical characteristics. The
selected significant variables were then used to construct a score classifying
the patients into groups with different expected benefits from rituximab
treatment. The reproducibility of such a score and grouping was validated
using the data of the remaining 100 patients of the trial (‘validation set’).
Results
Patient characteristics
The main characteristics of the 306 patients enrolled and of
their disease are summarized in Table 1. Thirty-two patients
were retrospectively judged ineligible: 27 because the pathology
review could not confirm the follicular or the mantle cell histol-
ogy and five because the disease was not measurable according
to protocol criteria. One patient was not evaluable because he
died before the trial treatment could be initiated.
Of the 273 eligible and evaluable patients, 61 were not ran-
domized to the second phase of the study because of disease
progression or major toxicity during the induction phase.
1676
Table 1. Main characteristics of eligible and evaluable patients and P values from preliminary univariate regression analyses
N % Effect on
response
P valueb
Effect on EFS
P valueb,c
Age <59/‡59 140/133 51/49
Sex M/F 135/138 49/51 0.008
Performance status 0/1/2 187/69/17 69/25/6
B-symptoms No/yes 186/83 69/31 0.03 0.02
Hemoglobin Grade 0/grade >0 188/85 69/31 0.0001 0.01
Platelets Grade 0/grade >0 236/36 87/13 0.03 0.002
WBC Grade 0/grade >0 224/49 82/18
ANC £3.7/>3.7 135/136 50/50
Neutrophiles Grade 0/grade >0 235/36 87/13
Lymphocytes Grade 0+1/grade >1 97/174 36/64 0.01
B lymphocytes £96.7/>96.7 106/l 84/107 44/56
T lymphocytes £675/>675 106/l 89/103 46/54
T-helper £353/>353 106/l 88/103 46/54 0.03
T-suppressor £236/>236 106/l 92/100 48/52
Natural killer £154/>154 106/l 88/104 46/54 0.03
Monocytes £0.4/>0.4 109/l 130/139 48/52
LDH £1· ULN/>1· ULN 168/100 63/37
IgG £8.4/>8.4 mg/ml 110/105 51/49
IgA £1.2/>1.2 mg/ml 106/109 49/51
IgM £0.6/>0.6 mg/ml 117/99 54/46
Ann Arbor stage I–III/IV 107/164 39/61 0.0002
Disease bulk <5/‡5 cm 130/143 48/52 0.0002 0.001
BM involvement No/yes 101/156 39/61 0.04 0.01
Histology FL/MCL 185/88 68/32 < 0.0001 0.0002
Growth pattern Other/diffuse 219/31 88/12 0.03 0.04
CD 43 Negative/positive 157/76 67/33 0.0008
MIB-1 <30%/‡30% 140/111 56/44
Previous chemotherapy No/yes 91/182 33/66 0.05 0.002
No. of previous chemotherapies £1/‡2 151/122 55/45 0.05 0.002
No. of previous chemo cycles £10/>11 87/90 49/51
Previous radiotherapy No/yes 228/45 84/16 0.04
Best previous response CR/PR/SD+PD 74/91/20 40/49/11
Fc-c receptor genotype FF/FV/VV 85/105/32 38/47/14 FV: 0.60
VV: 0.005
Characteristics at randomization (N = 212)
Performance status 0/1 161/51 76/24
Hemoglobin grade 0/grade >0 161/51 76/24 0.003
Platelets grade 0/grade >0 188/23 89/11
WBC grade 0/grade >0 171/41 81/19
ANC £3.7/>3.7 107/104 51/49
Lymphocytes grade 0+1/grade>1 73/138 35/65 0.002
Monocytes £0.4/>0.4 109/l 109/100 52/48
LDH £1·ULN/>1· ULN 150/61 71/29
IgG £8.4/>8.4 mg/ml 83/87 49/51
IgA £1.2/>1.2 mg/ml 76/94 45/55
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Predictive factors for response
The response rate to rituximab induction in the 273 eligible
and evaluable cases was 44% (38% partial response and 6%
complete response). Among 33 factors assessed, 15 were found
potentially predictive for response (Table 1). The favorable
factors finally selected by the stepwise procedure were disease
bulk <5 cm, follicular histology, normal hemoglobin and low
blood lymphocyte count (CTC toxicity grade >1), all deter-
mined at treatment start (Table 2).
Factors associated with event free survival
At a median follow-up of 4.5 years, the EFS for the 212
randomized patients was 11.2 months in arm A and 17.9 months
in arm B (P = 0.005) (Figure 1). The preliminary univariate
analyses showed that 14 baseline characteristics and five char-
acteristics at randomization have a potentially significant im-
pact on EFS (Table 1). Favorable factors finally selected by
the stepwise procedure, after taking treatment arm into account,
were: having responded to rituximab induction, Ann Arbor stage
I–III, having received not more than one previous line of
therapy, disease bulk <5 cm and high blood lymphocyte count
(CTC toxicity grade £1) at randomization (Table 3; the final
model was based on 197 patients). None of the lymphocyte
subtypes alone was found to be responsible for this latter effect.
Repeating the model selection procedure in patients whose
Fc-c receptor genotype was known revealed that Fc-c receptor
with a VV genotype is an additional independent favorable
factor for EFS (Table 4; the model was based on 171 patients).
Figure 2 suggests that the effect is possibly only present in
FL patients. However, a histology–genotype interaction was
not selected by the stepwise procedure, although a log-rank
P value of 0.004 was observed in a comparison between different
genotypes in FL patients (in MCL: P = 0.2).
Prediction score for EFS after rituximab
The unfavorable baseline clinical characteristics selected by
a stepwise procedure in the training set of 206 patients were:
MCL histology, stage IV, bulky disease, previous chemotherapy
and low hemoglobin (CTC toxicity grade >0). The prediction
score was then constructed as the number of unfavorable char-
acteristics present within each patient, with the score ranging
from 0 to 5. The EFS curves stratified by prediction score for
patients in the training set were very similar to those for
patients in the validation set (Figure 3). The similarity suggested
validity of the score. As suggested by the EFS curves, patients
could be classified into three groups: high-benefit group with
score 0–1, intermediate-benefit group with score 2–3 and low-
benefit group with score 4–5. By applying such grouping to the
whole population of 212 randomized patients, the median
EFS in arm A was 19.8 months in the high-benefit group, 11.0
months in the intermediate-benefit group and 5.1 months in the
Table 1. (Continued)
N % Effect on
response
P valueb
Effect on EFS
P valueb,c
IgM £0.6/>0.6 mg/ml 85/86 50/50
Disease bulk <5/‡5 cm 110/102 52/48 <0.0001
BM involvement No/yes 88/113 44/56 0.004
Histology FL/MCL 151/61 71/29 0.002
Response to induction rituximab No/yes 92/120 43/57 <0.0001
aAll continuous variables were dichotomized at their median values among all patients.
bOnly P values £0.05 are reported.
cThe P values for EFS came from Cox regression model including a covariate for treatment arm, with or without a further covariate for interaction.
Table 2. Independent predictive factors for response to induction
treatment selected by a stepwise procedure (n = 271)
Factor P value Odds
ratio
Confidence
interval
Histology FL/MCL 0.003 2.4 (1.4–4.4)
Hemoglobin Grade 0/grade >0 0.003 2.4 (1.3–4.4)
Lymphocytes Grade >1/0+1 0.02 2.0 (1.1–3.5)
Disease bulk <5/‡5 cm 0.0006 2.5 (1.5–4.3)
Event-free survival (years)
0 1 2 3 4 5
0.0
0.2
0.4
0.6
0.8
1.0 p=0.005
Observation
Consolidation
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Figure 1. EFS of 212 patients with FL or MCL randomized to receive
rituximab at the standard (arm A) or the prolonged schedule (arm B). The
prolonged schedule yields significantly longer EFS.
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low-benefit groups. For arm B the corresponding median values
were 42.3, 17.2 and 7.3 months (Figure 4). The benefit of
prolonged rituximab treatment seems to be noticeable only in
patients with fewer unfavorable characteristics.
Effects on the immune system
Data on lymphocyte subsets at baseline are available on 129 of
212 randomized patients, and on fewer cases at later time points
during the study. The baseline levels of T-helper, T-suppressor,
NK and B lymphocytes were lower than the normal ranges in
almost half of the patients. T-helper, T-suppressor and NK cells
remained stable all along the study in both arms, while circulat-
ing B cells showed a reduction to median level 20% of baseline
after 8–12 weeks from treatment start (P <0.0001). After 1 year,
the tendency of B-cell recovery was seen in arm A (median
level 81% of baseline, n = 22) but not in arm B (median level
50% of baseline, n = 35); this latter group took 6 months longer
to recover to baseline values (Figure 5).
Data on immunoglobulin levels at baseline are available on
90 of 212 randomized patients, and the number of available
observations decreased as the follow-up proceeded. Because
immunoglobulins were measured locally in each institution,
with different methods and normal values, the variation in their
levels was evaluated as a ratio to the baseline value. IgG and
IgA remained stable in both arms during treatment, while the
IgM levels evolved with a different pattern in the two treatment
arms: after 1 year the median IgM level had decreased to
73% of baseline in arm B (n = 50) whereas in arm A the median
level had recovered to 100% (n = 30, P = 0.007) (Figure 5).
Infections and second tumors
In the 306 patients treated, serious adverse events possibly
or probably related to rituximab treatment were 13 infections,
six cardiac events and five intestinal complications, resulting
in seven deaths (four cardiac, two infectious, one intestinal).
Further 11 serious adverse events were all non-fatal and of var-
ious nature (infusion reaction, cytopenias, renal, neurologic,
metabolic). The incidence of these reactions was similar in
arms A and B.
Of the 306 patients treated, 47 developed an infection: 27 dur-
ing the induction phase and 20 during the post-randomization
phase (eight in arm A and 12 in arm B). Of these 20 infec-
tions seven were severe (life-threatening or requiring hospit-
alization): two in arm A (pneumonia and candida stomatitis)
and five in arm B (two pneumonia, one viral hepatitis, one
cholecystitis and one severe paradontosis). The recovery of B
cells and IgM tended to be slower in patients who experi-
enced an infection compared with patients without infections
(difference not significant).
There were 16 cases of second tumor (five MDS/AML and
11 solid tumours): 10/202 in patients receiving induction only,
6 of 104 in patients receiving prolonged treatment.
Discussion
This is the largest study on clinical and biological predictive
factors for activity of single-agent rituximab. Besides being
based on a large patient set, the analyzed factors include not
only the classical clinical patient characteristics, but also an im-
portant number of pathology data, baseline and after-treatment
lymphocyte subsets, Fc-c receptor genotype and prospectively
collected data on toxicity with a long follow-up.
Some of our predictive factors are common predictive factors
in all cancer patients undergoing chemotherapy: parameters as-
sociated with the amount of disease (stage and disease bulk),
with the impact of the disease on patient homeostasis (hemo-
globin level) or with the extent of previous treatment (number of
previous therapy regimens). The lower chance of response in
MCL patients compared with FL patients also reflects what is
known for chemotherapy in general, and the observation that
responders do better than non-responders is common as well.
Compared with other studies of single-agent rituximab, in-
cluding enough cases to allow a multivariate analysis, we con-
firm the favorable role of FL histology for response as in the
study by McLaughlin [9]. Parameters describing previous treat-
ment history or disease extension were also found to have pre-
dictive influence by others, although the significant descriptive
parameters were not the same as in our analysis [9, 10].
Table 3. Independent predictive factors for EFS selected by a stepwise
procedure (n = 197)
Factor P value Hazard
ratio
Confidence
interval
Response at
week 12
CR+PR/SD+PD <0.0001 0.4 0.3–0.5
No. of previous
chemo regimens
£1/‡2 0.01 0.7 0.5–0.9
Ann Arbor stage I–III/IV <0.0001 0.4 0.3–0.6
Lymphocytes at
randomization
Grade 0+1/>1 0.02 0.6 0.4–0.9
Disease bulk at
baseline
<5/‡5 cm 0.05 0.7 0.5–1.0
Treatment Consolidation/
observation
0.0004 0.6 0.4–0.8
Table 4. Independent predictive factors for EFS when including Fc-c
receptor genotype selected by a stepwise procedure (n = 171)
Factor P value Hazard
ratio
Confidence
interval
Response at
week 12
CR+PR/SD+PD <0.0001 0.4 0.3–0.5
No. of previous
chemo regimens
£1/‡2 0.01 0.6 0.4–0.9
Ann Arbor stage I–III/IV 0.0001 0.5 0.4–0.7
Treatment Consolidation/
observation
0.0012 0.6 0.4–0.8
Fc-c receptor
genotype
VV/not VV 0.01 0.5 0.3–0.9
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Other results from our study are more puzzling. First, it
seems surprising that factors influencing response and factors
affecting EFS are not the same. For instance, lymphomas with
follicular histology have a higher chance of responding to
rituximab, but histology was not included in the selected mul-
tivariate model for EFS. Possible explanations are: (1) different
patient sets—more patients were included for response analy-
ses than for EFS analyses (limited to randomized patients who
did not progress under induction treatment); (2) confounding
effect—since histology plays an important role on response to
induction treatment, its impact on EFS might be partially con-
founded by the effect of response to induction treatment
that was selected in the multivariate EFS model; (3) selection
procedure—applying different selection procedures might re-
sult in different models, hence the models presented in this
report should not be considered as 100% definitive. Overall,
the fact that histology was not selected in the EFS model does
not mean that it does not exert influence on EFS. One piece of
evidence is that histology was selected in the prediction score
model in which non-randomized patients were also included.
On the other hand, patient’s genotype for the Fc-c III receptor
influences EFS (only in FL) but not the chance of responding.
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Event-free survival
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Figure 2. Effect of patient’s Fc-c III receptor genotype on EFS. A VV genotype seems to be favorable in FL patients, but irrelevant in MCL patients.
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Figure 3. EFS stratified by prediction score, in the randomly selected ‘training’ and ‘validation’ sets of patients. The score is given for each patient as
the number of present unfavorable characteristics among: MCL histology, stage IV, bulky disease, previous chemotherapy or hemoglobin level lower
than normal.
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Finally, a lower baseline lymphocyte count predicts response,
but a higher lymphocyte count after induction is associated
with better EFS. Analogy to the three explanations above could
also be applied here. In addition, a tentative biological explan-
ation for these apparent contradictions could be that of the
several mechanisms of action of rituximab, one (activation of
the complement) is predominant during the induction phase and
another one (the more lymphocyte- and Fc-c dependent ADCC
[antibody dependent cell cytotoxicity]) is more active during
the observation/prolonged phase. If this was true, the failure
of prolonged rituximab to extend EFS in MCL [6] could be
attributed to the lack of Fc-c mediated ADCC, as our data
suggests that Fc-c genotype is not a predictive factor in MCL.
The observation that the effect of rituximab is Fc-c dependent in
some lymphomas (as FL or lymphoplasmocytic) and not in
others (as MCL or chronic lymphocitic leukemia, CLL) was
made by other authors as well [11–13].
Our data also exhibited a relatively long immunosuppression
caused by the prolonged schedule of rituximab, but not associ-
ated with an increase of clinically relevant immunosuppression-
associated pathologies as infections or second tumors.
In conclusion, for patients with follicular lymphoma and not
suitable for an aggressive treatment, single-agent rituximab is
confirmed to be a valid option, particularly if patients present
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Figure 4. EFS stratified by treatment, separately for each benefit group derived from prediction score. Prolonged treatment with rituximab appears more
effective in patients presenting with a lower number of adverse factors.
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Figure 5. Effect of rituximab on the immune system. Patients treated with the prolonged schedule experienced a longer B-cell depletion and a longer
IgM reduction.
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with a low tumor load and normal blood counts. In these cases
prolonged treatment results in significantly longer EFS. Some of
these patients may, in some centres, be managed by a watch and
wait policy, and studies are ongoing comparing these two strat-
egies in this favorable population.
Even though the extended schedule causes a more prolonged
reduction of B cell and IgM levels, no additional toxicity is seen.
Because the response rate to rituximab is not dependent on
the presence of lymphocytes and on Fc-c receptor genotype,
while on the other hand EFS is dependent on them, we raise
the hypothesis that the mechanism of action of rituximab may
differ during treatment: cytotoxic cell-independent during the
early phase and cytotoxic cell-dependent during the later phase.
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